Canaccord initiated coverage of Curaleaf (CURLF) with a Buy rating and C$5 price target The winds of regulatory change are finally starting to blow and any material change to the backdrop ahead of the midterm elections will drive a re-rating of the space, the analyst tells investors in a research note. Curaleaf continues to elevate its offering, which should allow the company to better moat its footprint and either remain the cannabis destination of choice for consumers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CURLF:
- Curaleaf Announces Executive Securities Disposition Plan
- Curaleaf to Announce Q3 2025 Financial Results
- Curaleaf opens new dispensaries in Florida and Ohio
- Curaleaf Joins S&P/TSX Composite Index, Boosting Cannabis Industry Credibility
- Curaleaf Joins S&P/TSX Composite Index, Boosting Market Visibility